TREAT CTC
BIG 1-12
TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)
Toggle Content
This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.
Pharmaceutical partners: Roche, Janssen Diagnostics
This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.
More To Explore
DECRESCENDO
DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share
